Why the study?
Does doxorubicin at clinical doses alter cardiac electrophysiology and proteinuria in dogs with tumors?
Population
9 dogs with tumors
Design
Preclinical
Follow-up
Up to 3 doses (measurements taken just before the next dose)
Authors
Loading...
May warrant ECG/proteinuria monitoring in doxorubicin-treated dogs; leaves open human translation and prospective validation.
Does doxorubicin at clinical doses alter cardiac electrophysiology and proteinuria in dogs with tumors?
Doxorubicin at clinical doses in dogs induces early signs of cardiac autonomic dysfunction, QTc prolongation, and proteinuria, suggesting the utility of routine ECG and proteinuria monitoring for early toxicity screening.
Buranakarl et al. (2014) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: